ACST Stock Forecast 2025-2026
Distance to ACST Price Targets
ACST Price Momentum
10 Quality Stocks Worth Considering Now
Researching Acasti Pharma (ACST) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ACST and similar high-potential opportunities.
Latest ACST Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, ACST has a bullish consensus with a median price target of $7.97 (ranging from $7.97 to $7.97). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $2.53, the median forecast implies a 215.0% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ACST Analyst Ratings
ACST Price Target Range
Latest ACST Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ACST.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 26, 2024 | HC Wainwright & Co. | Oren Livnat | Buy | Reiterates | $12.00 |
| Sep 26, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $8.00 |
| Feb 7, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Initiates | $6.00 |
| Feb 15, 2023 | EF Hutton | Constantine Davides | Buy | Reiterates | $2.50 |
| Dec 19, 2022 | EF Hutton | Constantine Davides | Buy | Initiates | $2.50 |
| Dec 15, 2022 | HC Wainwright & Co. | Oren Livnat | Buy | Initiates | $2.40 |
| Dec 22, 2021 | Oppenheimer | Leland Gershell | Outperform | Initiates | $6.00 |
| Dec 21, 2021 | Oppenheimer | Leland Gershell | Outperform | Initiates | $6.00 |
| Nov 25, 2020 | B. Riley FBR | Neutral | Downgrade | $0.00 | |
| Nov 25, 2020 | H.C. Wainwright | Buy | Maintains | $0.00 | |
| Nov 25, 2020 | Benchmark | Speculative Buy | Initiates | $0.00 | |
| Nov 25, 2020 | Oppenheimer | Perform | Downgrade | $0.00 | |
| Nov 25, 2020 | Aegis Capital | Hold | Downgrade | $0.00 | |
| Sep 2, 2020 | Aegis Capital | Nathan Weinstein | Hold | Downgrade | $0.25 |
| Sep 1, 2020 | Oppenheimer | Perform | Downgrade | $0.00 | |
| Sep 1, 2020 | B. Riley Securities | Mike Crawford | Neutral | Downgrade | $0.50 |
| Sep 1, 2020 | B. Riley FBR | Neutral | Downgrade | $0.00 | |
| Jul 6, 2020 | B. Riley FBR | Buy | Upgrade | $0.00 | |
| May 6, 2020 | Aegis Capital | Nathan Weinstein | Buy | Maintains | $2.15 |
| Feb 18, 2020 | H.C. Wainwright | Buy | Maintains | $0.00 |
Grace Therapeutics Inc. (ACST) Competitors
The following stocks are similar to Acasti Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Grace Therapeutics Inc. (ACST) Financial Data
Grace Therapeutics Inc. has a market capitalization of $34.17M with a P/E ratio of -1.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -18.6%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Grace Therapeutics Inc. (ACST) Business Model
About Grace Therapeutics Inc.
Develops innovative therapies for rare diseases.
Grace Therapeutics Inc. operates by reformulating existing molecules to enhance their drug delivery systems, improving bioavailability and therapeutic outcomes. The company generates revenue by addressing unmet medical needs in rare and complex diseases, thus creating novel treatment options that may lead to market opportunities both domestically and internationally.
The company is committed to rigorous research and development, positioning itself as a leader in personalized medicine. Its collaborations and strategic initiatives further enhance its role in the pharmaceutical industry, making it a significant entity in advancing healthcare solutions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
0
CEO
Mr. Prashant Kohli
Country
United States
IPO Year
2012
Website
www.acastipharma.comGrace Therapeutics Inc. (ACST) Latest News & Analysis
Acasti Pharma Inc. will change its name to Grace Therapeutics, Inc. and start trading as "GRCE" on Nasdaq from October 28, 2024. A virtual event is scheduled for November 20.
The name change to Grace Therapeutics and trading symbol "GRCE" signals a strategic branding shift, potentially enhancing market perception and investor interest in the company's rare disease treatment.
Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104
6 months agoData readout is anticipated in early 2025, with a New Drug Application (NDA) submission expected in the first half of 2025.
The timeline for data readouts and NDA submission indicates potential upcoming approvals, impacting stock prices and market sentiment for related companies.
Acasti Pharma Inc. (Nasdaq: ACST) will participate in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, focusing on its GTX-104 treatment for aSAH.
Acasti Pharma's participation in a major investment conference highlights its progress with GTX-104, potentially attracting investor interest and impacting stock performance.
Acasti Pharma Inc. reported its financial results for Q2 2024, focusing on GTX-104, an injectable treatment for aneurysmal subarachnoid hemorrhage, addressing a significant medical need.
Acasti Pharma's financial results and progress on GTX-104 indicate potential growth and investment opportunities in the biopharma sector, particularly for treatments addressing rare diseases.
Acasti Pharma (ACST) and Cigna (CI) have been evaluated against their sector performance for the year, indicating their relative standing in the market.
The performance comparison of Acasti Pharma and Cigna against their sector indicates potential investment opportunities or risks, influencing stock valuations and investment strategies.
Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial
8 months agoThe company expects to complete patient enrollment in the STRIVE-ON Trial by late 2024 to early 2025, with a potential NDA submission planned for the first half of 2025.
Completion of patient enrollment and potential NDA submission timelines indicate significant progress in drug development, impacting future revenue and stock performance for the company.
Frequently Asked Questions About ACST Stock
What is Grace Therapeutics Inc.'s (ACST) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Grace Therapeutics Inc. (ACST) has a median price target of $7.97. The highest price target is $7.97 and the lowest is $7.97.
Is ACST stock a good investment in 2025?
According to current analyst ratings, ACST has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.53. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ACST stock?
Wall Street analysts predict ACST stock could reach $7.97 in the next 12 months. This represents a 215.0% increase from the current price of $2.53. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Grace Therapeutics Inc.'s business model?
Grace Therapeutics Inc. operates by reformulating existing molecules to enhance their drug delivery systems, improving bioavailability and therapeutic outcomes. The company generates revenue by addressing unmet medical needs in rare and complex diseases, thus creating novel treatment options that may lead to market opportunities both domestically and internationally.
What is the highest forecasted price for ACST Grace Therapeutics Inc.?
The highest price target for ACST is $7.97 from at , which represents a 215.0% increase from the current price of $2.53.
What is the lowest forecasted price for ACST Grace Therapeutics Inc.?
The lowest price target for ACST is $7.97 from at , which represents a 215.0% increase from the current price of $2.53.
What is the overall ACST consensus from analysts for Grace Therapeutics Inc.?
The overall analyst consensus for ACST is bullish. Out of 7 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $7.97.
How accurate are ACST stock price projections?
Stock price projections, including those for Grace Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
